Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | SCN1A | P35498 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171264 | 0.92 | HRH3 (0.79) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL12835047 | 0.90 | ALDH1A1 (0.72) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL10200149 | 0.89 | ALDH1A1 (0.70) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL29508217 | 0.87 | ALDH1A1 (0.88) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL14570561 | 0.86 | NPC1 (0.65) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL14577989 | 0.86 | NPC1 (0.69) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL8337754 | 0.84 | HRH3 (0.70) | ALDH1A1HRH3LTA4HKDM4E | |
| SCHEMBL15834053 | 0.84 | HRH3 (0.66) | HRH3LTA4HKDM4E | |
| SCHEMBL14149490 | 0.84 | NPC1 (0.62) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 | |
| SCHEMBL4485540 | 0.84 | LTA4H (0.69) | ALDH1A1MAPK1CYP1A2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| WO-2004000842-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO (3, 4-B) -QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-31 | — | — | WO | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ALDH1A1 208/4885MAPK1 203/4885CYP1A2 1987/4885 |
| US-20200054643-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | BMP1, BMP4, BMPR2 | ALDH1A1 4488/4885MAPK1 435/4885CYP1A2 4654/4885 |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | ALDH1A1 1744/4885MAPK1 412/4885CYP1A2 3051/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | ALDH1A1 4428/4885MAPK1 335/4885CYP1A2 3921/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | ALDH1A1 4790/4885MAPK1 144/4885CYP1A2 4852/4885 |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | ALDH1A1 3729/4885MAPK1 437/4885CYP1A2 3850/4885 |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | ALDH1A1 3729/4885MAPK1 437/4885CYP1A2 3850/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | ALDH1A1 1592/4885MAPK1 4778/4885CYP1A2 1432/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | ALDH1A1 3337/4885MAPK1 2930/4885CYP1A2 4360/4885 |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | ALDH1A1 3729/4885MAPK1 437/4885CYP1A2 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.